Leukemia Clinical Trials in North Carolina

Showing 341-360 of 1,513 trials

Not Yet Recruiting41 miles

A Long-term Follow-up Study of Patients With ARD103 CAR-T Cell Therapies

NCT06906380

This study will evaluate the long-term safety of ARD103 cellular therapies

Acute Myeloid Leukemia, in RelapseAcute Myeloid Leukemia, in Relapsed or RefractoryMDS (Myelodysplastic Syndrome)

ARCE Therapeutics, Inc.49 participantsStarted Mar 2026

Charlotte, North Carolina, United States • Winston-Salem, North Carolina, United States • Houston, Texas, United States

Not Yet Recruiting46 miles

Study of Oral Food Challenge Biomarkers (SAFER)

NCT07279467

This is a multi-center, mechanistic study. It is designed to learn more about signs in the body, called biomarkers, that might show if someone will have a reaction to peanut during a feeding test. The trial will enroll children ages 12 months to17 years old who are suspected of having an allergy to peanut. The primary objective is to identify a biomarker (or a combination of biomarkers) that will predict oral food challenge (OFC) (feeding test) results for participants with suspected peanut allergy.

Allergy

National Institute of Allergy and Infectious Diseases (NIAID)500 participantsStarted Apr 2026

Little Rock, Arkansas, United States • Palo Alto, California, United States • Chicago, Illinois, United States +7 more locations

A Long-term Follow-up Study of Patients With ARD103 CAR-T Cell Therapies

Study of Oral Food Challenge Biomarkers (SAFER)

Leukemia Trials in Other Cities

Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations

AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

MAGE A10ᶜ⁷⁹⁶T for Advanced NSCLC

LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC

ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies

A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor

Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies

Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML

Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer

Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers

Pevonedistat, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia

Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation

UNITY VCS Vitreoretinal Surgery

A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.

A Study to Investigate Atezolizumab Subcutaneous in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Other Conditions in North Carolina